Emerging topics in pediatric bone and mineral disorders 2008

Area of Science:

• Endocrinology
• Mineral Metabolism
• Nephrology

Background:

• The calcium sensing receptor (CaSR) regulates calcium homeostasis by controlling parathyroid hormone secretion and renal calcium reabsorption.
• Fibroblast growth factor 23 (FGF-23) is essential for phosphorus and vitamin D metabolism, acting on the kidneys.
• Dysregulation of CaSR and FGF-23 leads to various metabolic bone diseases and impacts chronic kidney disease progression.

Purpose of the Study:

• To elucidate the distinct and interconnected roles of CaSR and FGF-23 in mineral metabolism.
• To highlight the clinical implications of CaSR mutations and FGF-23 dysregulation.
• To discuss the therapeutic potential of CaSR agonists (calcimimetics) and the significance of FGF-23 in disease monitoring.

Main Methods:

• Review of existing literature on CaSR and FGF-23.
• Analysis of the physiological functions and pathological consequences of CaSR and FGF-23.
• Examination of therapeutic strategies targeting these pathways.

Main Results:

• CaSR mutations cause hypercalcemia or hypoparathyroidism, while calcimimetics treat secondary hyperparathyroidism.
• Altered FGF-23 levels result in hypophosphatemia or hyperphosphatemia, with associated bone and soft tissue abnormalities.
• Elevated FGF-23 levels are being explored as markers for chronic kidney disease progression.

Conclusions:

• CaSR and FGF-23 are critical for maintaining mineral balance, with CaSR primarily involved in calcium and FGF-23 in phosphorus and vitamin D regulation.
• Imbalances in these pathways lead to significant clinical conditions, including rickets, osteomalacia, and hyperparathyroidism.
• Further research into CaSR and FGF-23 pathways offers potential for novel therapeutic interventions and improved disease management, particularly in chronic kidney disease.